For planned acquisitions or licensing, a careful analysis of CMCl factors is vital to ensure no problem areas are overlooked.
Developing comprehensive chemistry, manufacturing, and controls programs are crucial to the success of a drug product. For planned acquisitions or licensing, a careful analysis of these critical factors is vital to ensure no problem areas are overlooked. Strategies for carrying out an effective due diligence exercise are described.
Read this article in Pharmaceutical Technology's Regulatory Sourcebook October 2020 eBook.
Pharmaceutical Technology
eBook: Regulatory Sourcebook
October 2020
Pages: 26–28
When referring to this article, please cite it as W. Lambert, “Due Diligence Assessment of CMC Activities," Pharmaceutical Technology Regulatory Sourcebook eBook (October 2020).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.